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Liposomes, spherical vesicles consisting of one or more phospholipid bilayers, were ﬁrst described in the mid 60s by Bangham
and coworkers. Since then, liposomes have made their way to the market. Today, numerous lab scale but only a few large-scale
techniques are available. However, a lot of these methods have serious limitations in terms of entrapment of sensitive molecules
due to their exposure to mechanical and/or chemical stress. This paper summarizes exclusively scalable techniques and focuses
on strengths, respectively, limitations in respect to industrial applicability. An additional point of view was taken to regulatory
requirements concerning liposomal drug formulations based on FDA and EMEA documents.
1.Introduction
1.1. History, Deﬁnition, and Classiﬁcation of Liposomes. The
story of success of liposomes was initiated by Bangham and
his colleagues in the early 1960s who observed that smears
of egg lecithin reacted with water to form quite intricate
structures.Theywereanalyzedbyelectronmicroscopyshow-
ing that a multitude of vesicles were formed spontaneously.
These more or less homogenous lipid vesicles were ﬁrst
called smectic mesophases [1]. Later on, a colleague of
Bangham termed them—more euphoniously—liposomes
[2]. In the following years, liposomes were primarily used as
artiﬁcial membrane models mimicking simple cell systems
for the investigation of transport functions and mechanisms,
permeation properties, as well as adhesion and fusion
kinetics. Liposomes were very soon recognized as promising
candidates for drug delivery systems [3, 4], and in this regard
more and more tailor-made formulations were investigated
for certain purposes such as medical applications, cosmetics
but also in food and agricultural industry, whereby the
main activities were focused on pharmaceutical and in
particular biopharmaceutical applications. The ﬁrst most
prominent products are Doxil (Sequus) and DaunoXome
(Gilead, Nexstar). Both are indicated as anticancer drugs,
which were successfully tested in clinical studies, followed by
theUSFoodandDrugAdministration(FDA)approvalinthe
1990s.
In general, liposomes are deﬁned as spherical vesicles
with particle sizes ranging from 30nm to several microme-
ters. They consist of one or more lipid bilayers surrounding
aqueous compartments, where the polar head groups are
oriented towards the interior and exterior aqueous phases.
However, self-aggregation of polar lipids is not restricted to
conventional bilayer structures which depend on tempera-
ture, molecular shape, and environmental and preparation
conditions but may self-assemble into various kinds of
colloidal particles [5, 6].
Due to this fact, the liposome family includes various
kinds of colloidal particles and structures which hamper
systematic classiﬁcation. However, they can be classiﬁed
by structure, composition, and preparation, as shown in
Table 1.
Technology and application are driven by two major
facts. First, the transfer from academic bench to a highly reg-
ulated, high technology industry was diﬃcult for liposome
technology because of the lack of appropriate methods to
produce large quantities in a controlled and reproducible
manner. Although several methods are suitable for large-
scale production, their development, implementation, and
quality control needed a certain time. Second, early clinical2 Journal of Drug Delivery
Table 1: Classiﬁcation of commonly known lipid vesicles according to their structures and/or preparation.
Identiﬁcation Deﬁnition
Archeosomes Archeosomes are vesicles consisting of archebacteria lipids which are chemically distinct from eukariotic and
prokariotic species. They are less sensitive to oxidative stress, high temperature, and alkaline pH [7, 8].
Cochleates
Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, allowing
the logic partitioning of polar molecule-based structures by phase separation. The liposome containing
two-phase polymer solution treated with positively charged molecules such as Ca2+ or Zn2+ forms a cochleate
precipitate of a particle dimension less than 1μm[ 9].
Dendrosomes
Dendrosomes represent a family of novel, nontoxic, neutral, biodegradable, covalent or self-assembled,
hyperbranched, dendritic, spheroidal nanoparticles which are easy to prepare, inexpensive, highly stable as well
as easy to handle and apply, compared with other existing synthetic vehicles for gene delivery [10].
Dried reconstituted
vesicles (DRV)
By this preparation technique, small, “empty” unilamellar vesicles, containing diﬀerent lipids or mixtures of
them, are prepared. After mixing those SUVs with the solubilised drug, dehydration is performed. By addition of
water, rehydration leads to the formation of large quantities of rather inhomogeneous, multilamellar vesicles
which need further processing [11].
Ethosomes
Ethosomal systems are much more eﬃcient at delivering to the skin, in terms of quantity and depth, than either
conventional liposomes or hydroalcoholic solutions. Ethosomal drug permeation through the skin was
demonstrated in diﬀusion cell experiments. Ethosomal systems composed of soy phosphatidylcholine and about
30% of ethanol were shown to contain multilamellar vesicles by electron microscopy [12].
Immunoliposomes Liposomes modiﬁed with antibodies, Fab’s, or peptide structures on the bilayer surface were established for in
vitro and in vivo application [13, 14].
Immunosomes
Immunosomes are prepared by the anchorage of glycoprotein molecules to preformed liposomes. Under the
electron microscope, immunosomes look like homogenous spherical vesicles (50–60nm) evenly covered with
spikes. Immunosomes have structural and immunogen characteristics closer to those of puriﬁed and inactivated
viruses than any other form of glycoprotein lipids association [15].
Immune stimulating
complex (ISCOM)
ISCOMs are spherical, micellar assemblies of about 40 nm. They are made of the saponin mixture Quil A,
cholesterol, and phospholipids. They contain amphiphilic antigens like membrane proteins. ISCOMs already
have a built-in adjuvant, Quillaja saponin, which is a structural part of the vehicle [16].
Lipoplexes Cationic lipid-DNA complexes, named lipoplexes, are eﬃcient carriers for cell transfection but have certain
drawbacks due to their toxicity. These toxic eﬀects may result from either cationic lipids or nucleic acids [17, 18].
LUVETs LUVETs are large unilamellar vesicles prepared by extrusion technique, mainly performed with high-pressure
systems [19].
Niosomes Niosomes are small unilamellar vesicles made from nonionic surfactants also called Novasomes. Their chemical
stability is comparable to that of archeosomes [20].
pH-sensitive liposomes
Four basic classes of pH-sensitive liposomes have been described previously. The ﬁrst class combines
polymorphic lipids, such as unsaturated phosphatidylethanolamines, with mild acidic amphiphiles that act as
stabilizers at neutral pH. This class of pH-sensitive liposomes has been the most intensively studied. The second
class includes liposomes composed of lipid derivatives resulting in increased permeability to encapsulated
solutes. A third class of pH-sensitive liposomes utilizes pH-sensitive peptides or reconstituted fusion proteins to
destabilize membranes at low pH. The ﬁnal and most current class of pH-sensitive liposomes uses pH-titratable
polymers to destabilize membranes following change of the polymer conformation at low pH [21].
Polymerised liposomes
Polymerized phosphatidyl choline vesicles (35–140nm) have been synthesized from lipids bearing one or two
methacrylate groups per monomer. Compared to nonpolymeric analogues, these vesicles exhibited improved
stability and controllable time-release properties [22].
Proliposomes Proliposomes are deﬁned as dry, free-ﬂowing particles that immediately form a liposomal dispersion on contact
with water [23, 24].
Proteosomes
Vesicles of bacterial origin were solubilised, followed by ammonium sulphate precipitation and dialysis against
detergent buﬀer. Proteins and peptides are noncovalently complexed to the membrane, making them highly
immunogenic [25].
Reverse-phase
evaporation vesicles
(REV)
Vesicles are formed by evaporation of oil in water emulsions resulting in large unilamellar liposomes [26].
Stealth liposomes
In the early 1990s, this liposome engineering process culminated with the observation that coating of liposomes
with polyethylene glycol (PEG), a synthetic hydrophilic polymer, would improve their stability and lengthens
their half-lives in circulation, rendering the use of glycolipids obsolete. PEG coating inhibits protein adsorption
and opsonization of liposomes, thereby avoiding or retarding liposome recognition by the reticuloendothelial
system (RES). These PEG-coated liposomes are also referred to as sterically stabilized or stealth liposomes. The
PEG stabilizing eﬀect results from local surface concentration of highly hydrated groups that sterically inhibit
both hydrophobic and electrostatic interactions of a variety of blood components at the liposome surface
[27–33].Journal of Drug Delivery 3
Table 1: Continued.
Identiﬁcation Deﬁnition
Temperature-sensitive
liposomes
Temperature-sensitive liposomes are considered to be a promising tool to achieve site-speciﬁc delivery of drugs.
Such liposomes have been prepared using lipids which undergo a gel-to-liquid crystalline phase transition a few
degrees above physiological temperature. However, temperature sensitization of liposomes has been attempted
using thermosensitive polymers. So far, functional liposomes have been developed according to this strategy
whose content release behavior, surface properties, and aﬃnity to cell surface can be controlled in a
temperature-dependent manner [34, 35].
Transfersomes Transfersomes consist of phosphatidylcholine and cholate and are ultradeformable vesicles with enhanced
skin-penetrating properties [36].
Virosomes
Virosomes are small unilamellar vesicles containing inﬂuenza hemagglutinin, by which they became fusogenic
with endocytic membranes. Coincorporation of other membrane antigens induces enhanced immune responses
[37].
trials were not as successful as expected because the stability
of conventional liposomes was low, caused by ineﬃcient
preparation, physical properties, and unfavorable choice of
lipids. Furthermore, they were to a great extent cleared by
liver and spleen very rapidly so that neither a prolonged
biological half-life nor speciﬁc targeting was achieved. More
stable conventional liposomes and second-generation for-
mulations, such as the stealth technology, gave new impulses
to the industry as well as to clinicians with the development
of industrial processes in the 1990s.
1.2. Liposome Technology and Regulatory Requirements. In
the last decade, the European Agency of the Evaluation of
MedicalProducts(EMA)aswellastheFDAhasimplemented
the subject of liposome into their guidelines.
Currently, EMA has not yet published any summarizing
document or guideline which is dealing exclusively with
nanoparticular structures. However, general aspects of lipo-
somes are covered in several guidelines such as “Note of
Guidance on the Quality, Preclinical and Clinical Aspects
of gene transfer medicinal,” and “Guideline on adjuvant in
vaccines for human use”.
Regarding appropriate regulations, FDA published a
draft version in 2001 entitled “Liposome Drug Products:
chemistry, manufacturing, and controls, human pharma-
cokinetics and bioavailability and labeling documentation.”
This draft version includes recommendations explicitly for
liposome drug products submitted in new drug applications
(NDAs).Indetail,recommendationsconcerningthesubmis-
sion of a new liposomal product are given regarding phys-
iochemical properties, description of manufacturing process
and process controls, and control of excipients and drug
products.Controlofexcipientsincludesallparameterswhich
are necessary to deﬁne lipid components, including descrip-
tion, characterization, manufacture, and stability. Control of
drug products is dealing with the speciﬁcations. In principal,
the recommendations of the ICH (International Conference
on Harmonization) guideline Q6A “Speciﬁcations, Test
Procedures and Acceptance criteria for New Drug Sub-
stances and New Drug Products: Chemical Substances” are
appropriate, but additional testing is necessary. In particular,
physicochemical parameters are critical for product quality
for each batch. Furthermore, aspects are addressed such as
assaying encapsulated and nonencapsulated drug substance,
lipid components, and degradation products, as well as in
vitro tests for drug release from liposomes. The second part
of this document is dealing with human pharmacokinetics
and bioavailability. In particular, requirements concerning
the quality and potency of bioanalytical methods are dis-
cussed. Therefore, the recommendations are focused on the
validation of these methods and the capability to distinguish
betweenencapsulatedandnonencapsulateddrugsubstances.
Similar recommendations are given for in vivo integrity and
stability considerations, respectively. For safety assessment,
validated in vitro assays are recommended to simulate the
liposomal release and/or interaction with lipoproteins and
other proteins in the blood. In an additional chapter, studies
for pharmacokinetics and bioavailability are recommended,
such as mass balance studies and pharmacokinetic studies.
Finally, general recommendations concerning the labeling
requirements are given. This draft guidance does not
provide recommendations on clinical eﬃcacy and safety
studies, nonclinical pharmacology and/or toxicology studies,
bioequivalence studies or those to document the sameness,
liposomal formulations of vaccine adjuvant or biologics, and
drug-lipid complexes. Unfortunately, during the intensive
discussion process no conclusion regarding the appropriate
approaches to access pharmacokinetics and bioavailability
was achieved. Hence, this document has only draft status to
this date.
In 2006, a reﬂection paper was published on nanotech-
nology-based medicinal products for human use reﬂecting
the current thinking and the initiatives by EMA in view of
recent developments in relation to this scope. As mentioned
in this document, medicinal products containing nanoparti-
cles, including liposomes, have already been authorized both
in EU and US under the existing regulatory frameworks.
Nevertheless, the European Commission has developed a
number of initiatives with emphasis on safety and ethical
considerations but also to evaluate the appropriateness of
existingmethodologiestoassessthepotentialrisksassociated
with nanotechnology. In this context, it is mentioned that
there is still insuﬃcient knowledge and data concerning
nanoparticles characterization, their detection and measure-
ment, the persistence of nanoparticles in humans and the
environment, and all aspects of toxicology related to these
particles to allow satisfactory risk assessments. In order to4 Journal of Drug Delivery
deal with this issue, the EMEA has created the Innovative
Task Force for the coordination of scientiﬁc and regulatory
competence. Because novel applications of nanotechnology
will span the regulatory boundaries between medicinal
products and medical devices, the mechanism of action will
be the key to decide whether a product should be regulated
as a medical product or a medical device. Furthermore, eval-
uation of the quality, safety, eﬃcacy, and risk management
must be discussed in more detail. In conclusion, it is likely
that the evaluation of such new products will require special
considerations. Therefore, EMA will promote this process
either to develop speciﬁc guidelines or for the update of
existing once.
2. PreparationTechniques
2.1. General Introduction into Techniques. Lipid molecules
have to be introduced into an aqueous environment for the
preparation of liposomes independent of liposome size and
structure. A general overview representing the correlation of
the way of lipid hydration, respectively, the way of primary
liposome formation with the resulting liposome structure,
was originally developed by Lasic [38].
Several ways of treating the lipids are known to support
the hydration of these molecules, as lipid molecules them-
selves are poorly soluble in aqueous compartments. These
procedures can be categorized as shown in Table 2.
Additional methods have been developed such as freeze
thawing, freeze drying, and extrusion. However, they are
all based on preformed vesicles. In the following sections,
liposome preparation techniques are described with respect
to the principle of lipid hydration/liposome formation as
well as process design and description. In addition, the
advantages and disadvantages of each technique are pointed
out.Furthermore,focusisgivenondiscussingthetechniques
with respect to their applicability regarding large-scale
production for clinical purposes and good manufacturing
practice (GMP) relevant issues.
3.MechanicalMethods
3.1. Preparation by Film Methods. Properties of lipid formu-
lations can vary depending on the composition (cationic,
anionic, and neutral lipid species). However, the same
preparation method can be used for all lipid vesicles
regardlessofcomposition.Thegeneralstepsoftheprocedure
are preparation of the lipids for hydration, hydration with
agitation, and sizing to a homogeneous distribution of
vesicles [40].
Since then, many diﬀerent variations of this method have
beendevelopeddiﬀeringintheorganicsolventsusedforlipid
solubilization, the way of lipid drying, and the way of ﬁlm
rehydration.
Despitethevariousmodiﬁcations,allthesemethodshave
in common that heterogeneous populations of multilamellar
liposomes are produced. However, vesicle size is inﬂuenced
by the lipid charge. Charged lipids form smaller liposomes
with less lamellae. Other inﬂuencing parameters are the
nature of the aqueous phase as well as energy and power
input of agitation.
The ﬁlm method has several advantages. It can be used
for all diﬀerent kinds of lipid mixtures. In addition, the
method is easy to perform, and high encapsulation rates of
lipid as well as aqueous soluble substances can be achieved
because high lipid concentrations can be used.
One major drawback of this method is the diﬃculty of
scaling up to several tens of liters. Furthermore, the process
becomes more time and cost intensive because additional
processing is recommended for a deﬁned liposome suspen-
sion, whereby product losses are generated.
Several downsizing techniques have been established in
order to make the heterogeneous vesicles more uniform. The
ﬁrst published downsizing method was sonication [41]. A
very high energy input based on cavitation is applied to the
liposomal dispersion either directly with a tip or indirectly in
a bath sonicator.
Other methods also aiming at breaking down the large
MLVs are homogenization techniques, either by shear or
pressure forces. In this group, methods are included such as
microﬂuidization, high-pressure homogenization, and shear
force-induced homogenization techniques.
Themostdeﬁnedmethodfordownsizingistheextrusion
technique whereby liposomes are forced through ﬁlters with
well deﬁned pores.
3.2. Homogenization Techniques. Similar to the ultrasound
methods,homogenizationtechniqueshavebeenusedinbiol-
ogy and microbiology for breaking up the cells. Therefore,
many scientists have used them for reducing the size and
number of lamellae of multilamellar liposomes.
The French press [42] originally was established for
breaking up cells under milder and more appropriate
conditions compared to the ultrasound techniques, because
lipids as well as proteins or other sensitive compounds
might be degraded during the sonication procedure. This
system is normally used in the volume of 1 to 40mL and
therefore is not suitable for large-scale production. However,
a scale-up-based strategy on this technique was established
as the microﬂuidization. This continuous and scaleable
variation of the French press technique enforces downsizing
of Liposomes by collision of larger vesicles at high pressure
in the interaction chamber of the microﬂuidizer.
Starting volumes from 50mL upwards are applicable,
and again high pressures are used for disruption of multi-
lamellar systems. The system works in a pressure range of
0–200 bar and is equipped with heating and cooling systems
to control sample temperature during processing [43]. The
liposome suspension passes the exchangeable oriﬁces several
times (up to thousands of passes). Liposomes are formed
in the size range from 50 to 100nm by this process. This
technique is suitable for large-scale production and sterile
liposome preparation.
In contrast to the microﬂuidizer, where the ﬂuid stream
is split and mixed by collision in a mixing chamber, homog-
enizers work on a diﬀerent principle. In a homogenizer, the
ﬂuid beam is pressed with high pressure through an oriﬁce,Journal of Drug Delivery 5
Table 2: Methods of liposome preparation and the resulting product. Partly from Lasic and Barenholz [39].
Method Vesicles
Mechanical methods
Vortex or hand shaking of phospholipid dispersions MLV
Extrusion through polycarbonate ﬁlters at low or medium pressure OLV, LUV
Extrusion through a French press cell “Microﬂuidizer” technique Mainly SUV
High-pressure homogenization Mainly SUV
Ultrasonic irritation SUV of minimal size
Bubbling of gas BSV
Methods based on replacement of organic solvent(s) by aqueous media
Removal of organic solvent(s) MLV, OLV, SUV
Use of water-immiscible solvents: ether and petroleum MLV, OLV, LUV
Ethanol injection method LUV
Ether infusion (solvent vaporization) LUV, OLV, MLV
Reverse-phase evaporation
Methods based on detergent removal
Gel exclusion chromatography SUV
“Slow” dialysis LUV, OLV, MLV
Fast dilution LUV, OLV
Other related techniques MLV, OLV, LUV, SUV
and this beam collides with a stainless steel wall. The
liposome suspension is continuously pumped through the
homogenizer system, where high pressures are generated to
downsize lipid vesicles [44].
The most prominent scalable downsizing method is
the extrusion. Size reduction is managed under mild and
more reproducible conditions compared to those discussed
above. In this method, preformed vesicles are forced through
deﬁnedmembranesbyamuchlowerpressureasdescribedin
the French press method. Extrusion through polycarbonate
ﬁlters was ﬁrst published by Olson et al. in 1979 [45].
Mayer et al. [19] performed extensive studies on varying
lipid compositions and the inﬂuence on extrusion behavior
and membrane properties. Depending on the apparatus and
scale, the diameters of these membranes range from 25 to
142mm. Lipex Biomembranes Inc., now Northern Lipids
Inc.,inventedavesselsystemforextrusionwhichismarketed
from the mL scale to several liters. As suggested for all
downsizing methods, liposomes should be extruded above
the Tc of the lipid composition; this system can be tempered.
The Lipex extruder system is available in a jacketed mode to
allow extrusion at higher temperatures.
An alternative is the Maximator device, established by
Schneider et al. [46]. It is a continuous extrusion device
working with a pumping system. The Maximator consists
of a thermostable glass supply vessel directly connected
to a pneumatic high pressure piston pump. The latter is
driven by either oxygen or nitrogen at pressures below
0.5MP a(5baror75psi).Thepropellantgasdoesnotcome
into contact with the liposome suspension. The resulting
operating (extrusion) pressure—which can be adjusted via
the reduction valve in the control device for the propellant
gas (3)—can be as high as 12MPa (120 bar or 1800psi) with
the current equipment.
All the presented extrusion methods have in common
that the reproducibility of downsizing is extremely high.
Systems with a heating device can either be used with
saturated and unsaturated lipids and are; therefore, all
purpose systems.
The main disadvantage of this method is the long-lasting
preparation starting with preformed liposomes, eventually
an additional freeze-thaw step, and ﬁnally the extrusion.
In these entire procedures, high product losses may be
generated, especially if clogging of the extrusion membranes
occurs, which may cause technical limitations with large-
scale production of high-priced goods.
4. Methods Based on Replacement of
OrganicSolvents byAqueous Media
The liposome preparation methods described in this section
have in common that organic solvents, either water miscible
or immiscible, are replaced by an aqueous solution. This
replacement is either performed by injection of the lipid
carrying organic solution into the aqueous phase—the injec-
tion methods—or by stepwise addition of aqueous phase to
the organic phase, in particular ethanol—the proliposome-
liposome method. In addition, the emulsiﬁcation methods,
namely, the reverse-phase evaporation method and the dou-
ble emulsion technique, are based on the replacement of a
water-immiscible solvent by an aqueous phase, thus forming
liposomes with high encapsulation rates of hydrophilic as
well as lipid phase soluble substances.
4.1. The Ethanol Injection Method. This technique was ﬁrst
reported in the early 1970s by Batzri and Korn [47]a so n e
of the ﬁrst alternatives for the preparation of SUVs without
sonication. By the immediate dilution of the ethanol in6 Journal of Drug Delivery
the aqueous phase, the lipid molecules precipitate and form
bilayer planar fragments [48] which themselves form into
liposomal systems, thereby encapsulating aqueous phase.
BatzriandKornperformedtheirexperimentswithaverylow
lipid concentration resulting in small liposomes and poor
encapsulation eﬃciency.
The preparation parameters inﬂuencing liposome size,
size distribution, and drug encapsulation eﬃciency were
investigated in more detail by Kremer et al. in 1977 [49].
They determined the lipid concentration in ethanol as the
only liposome formation inﬂuencing parameter. Neither
stirring rate of the aqueous phase nor injection velocity had
a signiﬁcant inﬂuence on liposome size and size distribution.
Another modiﬁed ethanol injection method was devel-
oped by Maitani et al. [50] which is more or less a com-
bination of the ethanol injection method, the proliposome
method, and the reverse-phase evaporation technique.
This method has many advantages as the technique is
in principle easy to scale up, and ethanol is a very harmless
solvent, accepted by the authorities also for injectables at a
maximum of 0.1% [51]. Some other solvents might also be
used,butonehastokeepin mindthe regulations forresidual
solvents classiﬁed into diﬀerent categories by the European
or US Pharmacopoeia. Stano et al. [52] emphasize the
advantageofpreparingmonomodaldistributedliposomesin
the size range of about 100nm and furthermore point out
the suitability of the entrapment of lipophilic substances. An
additional advance is the improvement of product shelf life
due to the absence of mechanical forces which might lead to
drug and/or lipid degradation.
Therefore, further development was initiated by several
groups. In 1995, Naeﬀ [53] published the development of
a liposome production technique in industrial scale based
on the ethanol injection technique. Their production system
was used for the liposomal encapsulation of econazole, an
imidazole derivative forthe topical treatment of dermatomy-
cosis, and combined the principles of the ethanol injection
system and high shear homogenization.
Additional production technology patents from several
companies were ﬁled dealing with liposome production
systems based on the ethanol injection technique (Optime,
Liposome Comp. Martin, Tenzel) [54–57].
Wagner et al. have also extensively worked in this ﬁeld,
leading to the development of the cross-ﬂow injection
system. Based on the ethanol injection technique, they
developedascalableandsterileproductiontechniqueleading
from the conventional batch process to a continuous proce-
dure [58].
Herein, the principal item is the cross-ﬂow injection
module [59], especially designed for this purpose. This
specially conceived unit has the beneﬁt of deﬁned and
characterized injection streams and permits liposome man-
ufacture regardless of production scale because scale is
determined only by free disposable vessel volumes. By this,
process development is performed in lab scale at a volume
of about 20mL. Once the parameters are deﬁned, an easy
scale-up can be performed by changing the process vessels
only.Inaddition,theseprocessvesselscanbesterilized,either
by steam or autoclavation. All raw materials such as buﬀer
solutions, lipid ethanol solution, and even N2 for applying
the injection pressure are transferred into the sanitized and
sterilized system via 0.2μm ﬁlters to guarantee an aseptic
production [60].
Liposome size can be controlled by the local lipid
concentration at the injection point which is deﬁned by the
lipid concentration in ethanol, the injection whole diameter,
the injection pressure, and the ﬂow rate of the aqueous
phase. By varying these parameters, diﬀerent liposome sizes
suitable for the intended purpose can be prepared. These
deﬁned process parameters are furthermore responsible for
highly reproducible results with respect to vesicle diameters
and encapsulation rates [61]. Tangential ﬂow ﬁltration is the
n e x tp r o c e s ss t e pt or e m o v ee t h a n o la sw e l la sn o te n t r a p p e d
drug.
Another important advantage of this method is the
suitability of the entrapment of many diﬀerent drug sub-
stances [61] such as large hydrophilic proteins by passive
encapsulation, small amphiphilic drugs by a one-step remote
loading technique, or membrane association of antigens for
vaccines [62].
4.2. Proliposome-Liposome Method. The proliposome-
liposome method is based on the conversion of the initial
proliposome preparation into a liposome dispersion by
dilution with an aqueous phase [50]. This method is
suitable for the encapsulation of a wide range of drugs
with varying solubility in water and alcohol and has
extremely high encapsulation eﬃciencies when compared
with other methods based on passive entrapment. Tur´ anek
and coworkers [63, 64] have developed a sterile liposome
production procedure based on this method. Reproducible
liposome preparation is feasible in a controlled manner
by exact controlling of the dilution rate and process
temperature. Additionally, the authors claim their method
as being easy to scale up, which makes this method an
alternative approach for the production of liposomes for
clinical application.
4.3. Reverse-Phase Evaporation (REV). Similarly to the above
presented injection methods, lipid is hydrated via solubi-
lization in an organic phase followed by introduction into
an aqueous phase. The organic phase should be immiscible
with the aqueous phase, thus an oil/water emulsion is
created, which is diluted with further aqueous phase for
liposome formation [65]. The advantage of this very popular
preparation technique is a very high encapsulation rate
up to 50%. One variation of the microemulsion tech-
nique, the double emulsion technique, further improves the
encapsulation rates and results in unilamellar liposomes
[26]. A possible drawback of this eﬃcient method is the
remaining solvent or the proof of their absence especially
for using them for pharmaceutical purposes. The other
important issue is large-scale production which might be
feasible if appropriate shear mixing devices for the creation
of the microemulsion and pumps for the dilution step are
available.Journal of Drug Delivery 7
5. Methods Based on Detergent Removal
In this group of liposome preparation procedures, deter-
gents, such as bile salts or alkylglycosides, are used for the
solubilization of lipids in micellar systems. In contrast to
lipids, detergents are highly soluble in both aqueous and
organic media. There is equilibrium between the detergent
molecules in the aqueous phase and the lipid environment
of the micelle. The size and shape of the resulting vesicles
are depending on the chemical nature of the detergent,
their concentration, and the lipids used. To date, the most
frequentlyappliedmethodformembraneproteinreconstitu-
tion involves the cosolubilization of membrane proteins and
phospholipids [66–68]. Common procedures of detergent
removal from the mixed micelles are dilution [69], gel chro-
matography [70], and dialysis through hollow ﬁbers [71]
or through membrane ﬁlters [72]. Additionally, detergents
can also be removed by adsorption to hydrophobic resins
or cyclodextrins [73]. Dialysis of mixed micelles against an
aqueous medium was ﬁrst described by Kagawa and Racker
[74]. This method for vesicle formation is based on the
retention of the micelle, whereas free detergent molecules are
eliminated. Goldin [72] describe the use of pure cellulose
for this approach. In order to gain better control in the
formation of proteoliposomes, Wagner et al. developed a
new technique, where they combine an advanced ethanol
injection technique, the cross-ﬂow injection technique [58],
withdetergentdilutionwithinoneoperationalstep.Thereby,
lipid vesicles are formed immediately after injection into a
micellar protein solution. As described earlier, the multiple
injection technique [59], previously used for high yield
passive encapsulation of water-soluble proteins, can be
adapted for this one-step detergent dilution/vesicle forming
process [62].
6. FinalRemarks
Numerous studies for the pharmaceutical application of
liposomes have appeared during the past few decades.
They have attracted great interest as models for biologi-
cal membranes, diagnostics, nutrients, and other bioactive
agents. Nevertheless, the pharmaceutical application, as drug
carriers for speciﬁc targeting, controlled, and/or sustained
release, as well as for vaccination, was and still is the driving
force for the development of innovative technologies. From
this expertise, one can derive that liposomes are versatile
carrier systems which need to be custom made in terms of
in vitro and in vivo properties. In the last decades, numerous
preparation techniques were established for this purpose,
whereby most of them are in particular suitable for the
laboratory and less for industrial approach. However, large
scale capacities are required for the preparation of clinical
material as well as for marketed products providing sterile,
well-characterized, and stable products. Unfortunately, the
availability of certain production methods as well as the
quality aspects depend on the characteristics of the lipids
themselves. This limits the choice of liposome types from
which one can select when optimizing liposome-based drug
therapy.
Though many preparation methods were investigated
in the 1980s and 1990s, little attention has been paid to
the transfer of technology to industry. Thus, presently the
advancement is primarily focused on large-scale manufac-
turing. Stringent control of the product is required to ensure
thepredictabletherapeuticeﬀect,whereasacceptancecriteria
have to be deﬁned for the quality as well as the process.
Additionally, qualityissuesregarding unwantedby-products,
such as residues of organic solvents and/or degradation
products, are just as important as pyrogen-free and sterile
conditions. In particular, the latter aspect still is a big issue
for industrial processes. Until now, no general acceptable
method could be successfully established. Commonly used
processes to achieve sterility for pharmaceutical products are
sterile ﬁltration or autoclaving. Both methods are of either
no or only limited suitability for liposomal drug products.
In many cases, degradation and/or unacceptable product
loss in combination with drug release and instability are
the consequences. Currently, many manufacturers try to
implement alternative strategies, such as lyophilization and
production processes in closed containments equipped with
sterile ﬁlter barriers, to solve this essential problem.
In conclusion, besides the development of new liposomal
drug formulations, researchers as well as manufacturers are
requiredtoestablishprocesseswhicharestateoftheartinthe
pharmaceutical industry. The realization of maybe future,
more complex liposome structures with advanced eﬃcacy
will to a great extent dependent on those achievements.
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